Group One Trading’s Black Diamond Therapeutics BDTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-1,618
Closed -$3.85K 7652
2025
Q4
$3.93K Sell
1,618
-2,767
-63% -$9.8K ﹤0.01% 7280
2025
Q3
$16.6K Buy
+4,385
New +$12.8K ﹤0.01% 6837
2025
Q2
Sell
-384
Closed -$740 7937
2025
Q1
$595 Buy
+384
New +$805 ﹤0.01% 7257
2024
Q4
Sell
-75,314
Closed -$216K 7268
2024
Q3
$328K Buy
75,314
+73,070
+3,256% +$398K ﹤0.01% 3180
2024
Q2
$10.5K Buy
2,244
+996
+80% +$5.35K ﹤0.01% 5627
2024
Q1
$6.33K Sell
1,248
-6,186
-83% -$24.9K ﹤0.01% 6086
2023
Q4
$20.9K Buy
+7,434
New +$17.4K ﹤0.01% 5723
2022
Q3
Sell
-1,495
Closed -$4.61K 7545
2022
Q2
$4K Buy
1,495
+700
+88% +$1.63K ﹤0.01% 7174
2022
Q1
$2K Sell
795
-400
-33% -$1.46K ﹤0.01% 7708
2021
Q4
$6K Sell
1,195
-800
-40% -$5.59K ﹤0.01% 7566
2021
Q3
$17K Sell
1,995
-200
-9% -$1.98K ﹤0.01% 7255
2021
Q2
$27K Buy
+2,195
New +$43.4K ﹤0.01% 7008

Other funds holding BDTX

Group One Trading's BDTX Position: Q1 2026 in Review

Group One Trading sold out of Black Diamond Therapeutics (BDTX) in Q1 2026, closing a stake of 1,618 shares — an estimated $3.85K sold.

Group One Trading first reported a position in BDTX in Q2 2021 and held it in 12 quarters. The position peaked at $328K in Q3 2024. 104 funds tracked by Wall St. Rank hold BDTX as of Q1 2026.

  • Group One Trading reported no remaining Black Diamond Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Group One Trading sold 1,618 Black Diamond Therapeutics shares in Q1 2026, an estimated $3.85K.
  • Group One Trading first reported a position in Black Diamond Therapeutics in Q2 2021 and held it in 12 quarters.
  • Group One Trading's Black Diamond Therapeutics position peaked at $328K in Q3 2024.
  • 104 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.